Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NASDAQ:CGTX NASDAQ:CYPH NASDAQ:LSTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$1.97-5.7%$2.63$1.93▼$4.94$112.88M3.222.06 million shs1.02 million shsCGTXCognition Therapeutics$1.29-5.1%$1.12$0.25▼$3.83$115.45M1.751.09 million shs1.10 million shsCYPHCypherpunk Technologies$0.52-47.1%$0.97$0.23▼$3.70$55.23M-0.024.43 million shs29.86 million shsLSTALisata Therapeutics$3.35-0.6%$3.74$1.81▼$5.07$30.51M0.81173,948 shs22,782 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-5.97%-11.26%-30.14%-8.37%-22.44%CGTXCognition Therapeutics-5.15%+9.32%+4.88%+25.24%+319.38%CYPHCypherpunk Technologies-47.14%-54.09%-54.09%+1.03%+28.13%LSTALisata Therapeutics-0.59%+3.08%+2.76%-19.86%+25.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$1.97-5.7%$2.63$1.93▼$4.94$112.88M3.222.06 million shs1.02 million shsCGTXCognition Therapeutics$1.29-5.1%$1.12$0.25▼$3.83$115.45M1.751.09 million shs1.10 million shsCYPHCypherpunk Technologies$0.52-47.1%$0.97$0.23▼$3.70$55.23M-0.024.43 million shs29.86 million shsLSTALisata Therapeutics$3.35-0.6%$3.74$1.81▼$5.07$30.51M0.81173,948 shs22,782 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-5.97%-11.26%-30.14%-8.37%-22.44%CGTXCognition Therapeutics-5.15%+9.32%+4.88%+25.24%+319.38%CYPHCypherpunk Technologies-47.14%-54.09%-54.09%+1.03%+28.13%LSTALisata Therapeutics-0.59%+3.08%+2.76%-19.86%+25.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 2.73Moderate Buy$10.00407.61% UpsideCGTXCognition Therapeutics 2.50Moderate Buy$3.33158.40% UpsideCYPHCypherpunk Technologies 1.00SellN/AN/ALSTALisata Therapeutics 1.67Reduce$15.00347.76% UpsideCurrent Analyst Ratings BreakdownLatest LSTA, CGTX, CYPH, and BDTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026BDTXBlack Diamond Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/22/2026BDTXBlack Diamond Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026CYPHCypherpunk Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D-)5/18/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/18/2026LSTALisata Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/15/2026LSTALisata Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral4/29/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/29/2026BDTXBlack Diamond Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.004/23/2026BDTXBlack Diamond Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/22/2026CYPHCypherpunk Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond Therapeutics$70M1.61$0.53 per share3.74$1.97 per share1.00CGTXCognition TherapeuticsN/AN/AN/AN/A$0.39 per shareN/ACYPHCypherpunk TechnologiesN/AN/AN/AN/A$1.83 per shareN/ALSTALisata Therapeutics$170K179.52N/AN/A$1.66 per share2.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics$22.37M-$0.77N/AN/AN/AN/A-30.18%-23.91%8/6/2026 (Estimated)CGTXCognition Therapeutics-$23.49M-$0.24N/AN/AN/AN/A-72.68%-53.07%8/6/2026 (Estimated)CYPHCypherpunk Technologies$4.82M-$0.02N/AN/AN/AN/A-48.33%-42.21%N/ALSTALisata Therapeutics-$16.59M-$1.86N/AN/AN/AN/A-103.54%-83.08%8/6/2026 (Estimated)Latest LSTA, CGTX, CYPH, and BDTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CYPHCypherpunk Technologies-$0.0406-$0.46-$0.4194-$0.46N/AN/A5/11/2026Q1 2026LSTALisata TherapeuticsN/A-$0.50N/A-$0.50N/AN/A5/7/2026Q1 2026BDTXBlack Diamond Therapeutics-$0.18-$0.16+$0.02-$0.16$25.00 millionN/A5/7/2026Q1 2026CGTXCognition Therapeutics-$0.06-$0.05+$0.01-$0.05$4.40 millionN/A3/26/2026Q4 2025CGTXCognition Therapeutics-$0.06-$0.02+$0.04-$0.02N/AN/A3/16/2026Q4 2025BDTXBlack Diamond Therapeutics-$0.18-$0.14+$0.04-$0.27$9.38 millionN/A3/12/2026Q4 2025LSTALisata Therapeutics-$0.74-$0.33+$0.41-$0.33N/A$0.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/ACGTXCognition TherapeuticsN/AN/AN/AN/AN/ACYPHCypherpunk TechnologiesN/AN/AN/AN/AN/ALSTALisata TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A8.468.46CGTXCognition TherapeuticsN/A5.925.92CYPHCypherpunk TechnologiesN/A27.2827.28LSTALisata TherapeuticsN/A4.234.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%CGTXCognition Therapeutics43.35%CYPHCypherpunk Technologies30.46%LSTALisata Therapeutics8.94%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics9.29%CGTXCognition Therapeutics11.11%CYPHCypherpunk Technologies3.50%LSTALisata Therapeutics9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9057.30 million51.98 millionOptionableCGTXCognition Therapeutics2089.50 million79.56 millionNot OptionableCYPHCypherpunk Technologies40106.46 million102.74 millionOptionableLSTALisata Therapeutics309.11 million8.23 millionNot OptionableLSTA, CGTX, CYPH, and BDTX HeadlinesRecent News About These CompaniesKuva and Lisata Therapeutics Tender Offer UpdateJune 1, 2026 | tennessean.comTHC Wainwright & Co. downgrades Lisata Therapeutics (LSTA)May 16, 2026 | msn.comLisata Therapeutics Amends Kuva Labs Merger Agreement TimelineMay 9, 2026 | theglobeandmail.comHalper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their ShareholdersMay 4, 2026 | globenewswire.comLisata Therapeutics Delays Tender Offer Launch in MergerApril 3, 2026 | tipranks.comLeading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum CommunicationsMarch 26, 2026 | businesswire.comLisata Therapeutics shares up 20% as Kuva Labs acquisition advancesMarch 10, 2026 | finance.yahoo.comLisata Therapeutics to be acquired by Kuva LabsMarch 9, 2026 | proactiveinvestors.comShareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public ShareholdersMarch 9, 2026 | prnewswire.comLisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.March 6, 2026 | globenewswire.comLisata Extends Kuva Labs Acquisition Term Sheet TimelineFebruary 27, 2026 | tipranks.comLisata Therapeutics (LSTA) price target decreased by 26.92% to 9.69February 4, 2026 | msn.comLisata Therapeutics ends Qilu certepetide collaboration dealJanuary 27, 2026 | tipranks.comLisata regains China rights to pancreatic cancer drugJanuary 27, 2026 | proactiveinvestors.comLisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for CertepetideJanuary 27, 2026 | globenewswire.comBrookline Capital downgrades Lisata Therapeutics (LSTA)January 22, 2026 | msn.comAll-Cash Buyout Sparks Breakout Move in Biotech NameJanuary 22, 2026 | theglobeandmail.comHow The Evolving Story For Lisata Therapeutics (LSTA) Is Reshaping Its Valuation OutlookJanuary 22, 2026 | finance.yahoo.comLisata Therapeutics, Inc.: Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender OfferJanuary 21, 2026 | finanznachrichten.deLisata stock soars after Kuva Labs acquisition offer at 85% premiumJanuary 21, 2026 | in.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLSTA, CGTX, CYPH, and BDTX Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$1.97 -0.12 (-5.74%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.98 +0.01 (+0.66%) As of 06/5/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Cognition Therapeutics NASDAQ:CGTX$1.29 -0.07 (-5.15%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.36 +0.07 (+5.66%) As of 06/5/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Cypherpunk Technologies NASDAQ:CYPH$0.52 -0.46 (-47.14%) As of 06/5/2026 04:00 PM EasternLeap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Lisata Therapeutics NASDAQ:LSTA$3.35 -0.02 (-0.59%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$3.31 -0.04 (-1.31%) As of 06/5/2026 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
